Both in Canada and the US, the most critical problem to be addressed for commercial exploitation of C. sativa is the possible unauthorized drug use of the plant. Indeed, the reason hemp cultivation was made illegal in North America was concern that the hemp crop was a drug menace. The drug potential is, for practical purposes, measured by the presence of THC. THC is the world’s most popular illicit chemical, and indeed the fourth most popular recreational drug, after caffeine, alcohol, and nicotine. “Industrial hemp” is a phrase that has become common to designate hemp used for commercial non-intoxicant purposes. Small and Cronquist (1976) split C. sativa into two subspecies: C. sativa subsp. sativa, with less than 0.3% (dry weight) of THC in the upper (reproductive) part of the plant, and C. sativa subsp. indica (Lam.) E. Small & Cronq. with more than 0.3% THC. This classification has since been adopted in the European Community, Canada, and parts of Australia as a dividing line between cultivars that can be legally cultivated under license and forms that are considered to have too high a drug potential. For a period, 0.3% was also the allowable THC content limit for cultivation of hemp in the Soviet Union. In the US, Drug Enforcement Agency guidelines issued Dec. 7, 1999 expressly allowed products with a THC content of less than 0.3% to enter the US without a license; but subsequently permissible levels have been a source of continuing contention. Marijuana in the illicit market typically has a THC content of 5% to 10% (levels as high as 25% have been reported), and as a point of interest, a current Canadian government experimental medicinal marijuana production contract calls for the production of 6% marijuana. As noted above, a level of about 1% THC is considered the threshold for marijuana to have intoxicating potential, so the 0.3% level is conservative, and some countries (e.g. parts of Australia, Switzerland) have permitted the cultivation of cultivars with higher levels. It should be appreciated that there is considerable variation in THC content in different parts of the plant. THC content increases in the following order: achenes (excluding bracts), roots, large stems, smaller stems, older and larger leaves, younger and smaller leaves, flowers, perigonal bracts covering both the female flowers and fruits. It is well known in the illicit trade how to screen off the more potent fractions of the plant in order to increase THC levels in resultant drug products. Nevertheless, a level of 0.3% THC in the flowering parts of the plant is reflective of material that is too low in intoxicant potential to actually be used practically for illicit production of marijuana or other types of cannabis drugs. Below, the problem of permissible levels of THC in food products made from hempseed is discussed.
In the United States, cannabis is overall the number four value crop, and is number one or two in many states including California, New York and Florida, averaging $3,000 per pound ($6,600/kg). Some believe it generates an estimated $36 billion market. Some have argued that this estimate is methodologically flawed, and makes unrealistic assumptions about the level of marijuana consumption. Other estimates claiming to correct for this flaw claim that the market is between $2.1-$4.3 billion. The United Nations Office on Drugs and Crime claims in its 2008 World Drug Report that typical U.S. retail prices are $10–15 per gram (approximately $280–420 per ounce). Street prices in North America are known to range from about $40–$400 per ounce ($1.4–$14/g), depending on quality.
One of CBD’s chief properties is its anticonvulsant nature. Clinical trials have shown that CBD is effective at reducing seizures in children, and the FDA is likely to approve Epidiolex, a pharmaceutical-grade version of CBD for this use, in summer 2018. Although CBD has been documented as an antiepileptic since 1881, CBD’s anticonvulsant mechanisms still remain unclear. Not enough studies have been conducted to understand this relationship fully. One possible explanation for CBD’s neuroprotective effects is its interaction with NMDA receptors, which play a key role in the overly active neuron activity that is a hallmark of epilepsy.
There are practical, if cruder alternatives to separate the long fiber for high-quality textile production, but in fact such techniques are used mostly for non-textile applications. This involves production of “whole fibers” (i.e. harvesting both the long fibers from the cortex and the shorter fibers from throughout the stem), and technologies that utilize shortened hemp fibers. This approach is currently dominant in western Europe and Canada, and commences with field dew retting (typically 2–3 weeks). A principal limitation is climatic—the local environment should be suitably but not excessively moist at the close of the harvest season. Once stalks are retted, dried, and baled, they are processed to extract the fiber. In traditional hemp processing, the long fiber was separated from the internal woody hurds in two steps, breaking (stalks were crushed under rollers that broke the woody core into short pieces, some of which were separated) and scutching (the remaining hurds, short fibers (“tow”) and long fibers (“line fiber, ” “long-line fiber”) were separated). A single, relatively expensive machine called a decorticator can do these two steps as one. In general in the EU and Canada, fibers are not separated into tow and line fibers, but are left as “whole fiber.” In western Europe, the fiber is often “cottonized,” i.e. chopped into short segments the size of cotton and flax fiber, so that the fibers can be processed on flax processing machinery, which is very much better developed than such machinery is for hemp. In North America the use of hemp for production of even crude textiles is marginal. Accordingly, the chief current fiber usages of North American, indeed of European hemp, are non-textile.
The 2014 Farm Bill legalized the sale of "non-viable hemp material" grown within states participating in the Hemp Pilot Program. This legislation defined hemp as cannabis containing less than 0.3% of THC delta-9, grown within the regulatory framework of the Hemp Pilot Program. The 2018 Farm Bill allowed for interstate commerce of hemp derived products, though these products still fall under the purview of the FDA.
Namaste, a Canadian cannabis company, also has relationships with Cannbit. They have invested in Cannbit as a cultivator and supplier of raw cannabis for their global ventures, some of which include coffee shop chains in Israel. Namaste has a 10% stake in Cannabit, and they intend to continue facilitating the import of MMJ from Israel to Canada as well as other jurisdictions once approved.
Fig. 8. Scanning electron micrographs of the abaxial surface of a perigonal bract (which envelops the fruit). These bracts are the most intoxicating part of the plant, and may contain 20% THC, dry weight. The resin is synthesized both in stalked and sessile glands. Multicellular secretory glands (of phallic appearance), some broken stalks of these (note cellular appearance), and unicellular cystolith hairs (claw-like structures) are pictured. Fig. 9. Some important cannabinoids of cannabis resin. D9-THC (delta-9 tetrahydrocannabinol) is the chief intoxicant chemical and predominates in intoxicant strains, while the isomer D8-THC is usually present in no more than trace amounts. CBD (cannabidiol) is the chief non-intoxicant chemical, and predominates in non-intoxicant strains; it has sedative effects. The non-intoxicant CBN (cannabinol) is a frequent degradation or oxidation product. The non-intoxicant cannabichromene (CBC) is typically found in trace amounts in intoxicant strains. The non-intoxicant cannabigerol (CBG) is considered to be a precursor of the other cannbinoids (see Fig. 10).
Many teens suffer from mental health issues in response to the pressures of society and social problems they encounter. Some of the key mental health issues seen in teens are: depression, eating disorders, and drug abuse. There are many ways to prevent these health issues from occurring such as communicating well with a teen suffering from mental health issues. Mental health can be treated and be attentive to teens' behavior.
The confusion between industrial hemp and marijuana is based on the visual similarities of widely differentiated varieties of plants. By definition, industrial hemp is high in fiber and low in active tetrahydrocannabinol (THC), the psychoactive ingredient in marijuana that makes some cannabis varieties a valued drug. Canada and the European Union maintain this distinction by strictly regulating the THC levels of industrial hemp, requiring it to be less than 0.3 percent, compared to THC levels of between 3 to 30 percent in marijuana.
HempWorx CBD is an interesting brand that has no issue with transparency in terms of how they operate as a business, and where they source their raw hemp plant material from. Also, one of the main things that stands out to me as that they’re one of the only companies I know of that offers specific dosing guidelines for a range of serious medical conditions. This is a bit odd, however, as they also make it clear that CBD is not approved by the FDA as a medicine, and thus none of their products are designed to “treat, cure, or prevent” any disease.
The legality of CBD in the US varies from state to state, but at the federal level, CBD is mysteriously classified as a Schedule I drug despite its sourcing. According to the federal government, Schedule I drugs are substances or chemicals with no currently accepted medical use and a high potential for abuse. Other Schedule I drugs include heroin, LSD, marijuana, and ecstasy. However, CBD can be purchased as a dietary supplement throughout the country despite the FDA’s official stance that CBD isn’t a supplement. The landscape of CBD legality in the US is exactly as confusing as it reads; that squirrely, perplexing itch at the back of your brain is cognitive dissonance, and it’s an entirely normal reaction.
There is certainly a need to utilize available germplasm sources in order to breed suitable cultivars for North America. A list of the 24 approved cultivars for the 2001 season in Canada is at www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/hemp.html. Most of these are regulated by the European Organization of Economic Cooperation and Development (OECD). These cultivars are “approved” for use in Canada not on agricultural criteria, but merely on the basis that they meet the THC criterion. Indeed, most of these are unsuitable or only marginally suitable for Canada (Small and Marcus 2000), and only a very few Canadian cultivars to date have been created. In Canada, every acquisition of hemp grown at a particular place and time must be tested for THC content by an independent laboratory and, under the industrial hemp regulations, fields of hemp with more than 0.3% THC may require destruction (a slight degree of flexibility is generally exercised). Importation of experimental hemp lines (i.e. other than the approved cultivars) requires importation licenses (as well as phytosanitary clearance of the shipment by the Canadian Food Inspection Agency), and the importation licenses require an indication that the THC contents are low.
The heat is very much on CBD oil sellers these days as the FDA continues to crack down on companies selling “questionable” (to put it nicely) hemp-based products. In fact, since 2015 – when the FDA first issued warning letters to multiple CBD sellers – the industry has been forced to clean up its act, at least in terms of manufacturing operations and brand transparency.
This is what you’ll want (or need) if you’re looking for a “light” reprieve from discomfort. Or if you’re trying a THC:CBD edible for the first time—without any of the unpleasant side effects. Or if you’re taking CBD on a daily basis as maintenance. I guess what I’m trying to say is that Plus’ pineapple and coconut gummies will do you no harm. It’s a safe bet for beginners.
Aqua, Sodium Acrylates Copolymer Lecithin, Glycerin, Allantoin, Sodium Hyaluronate, Stearic Acid, Cetyl Alcohol, Stearyl Alcohol, Glycol Distearate, Menthol, Glyceryl Stearate, PEG-100 Stearate, Tocopheryl Acetate, Emu Oil, Cocos Nucifera (Coconut Oil), Squalene, Cannabis Sativa Seed Oil (Hemp Seed Oil)< Arnica Montana Flower Extract, Boswellia Serrata Resin Extract, Aloe Barbadensis Leaf Juice, Phenoxyethanol, Ethylhexylglycerin, Gluconolactone, Sodium Benzoate, Calcium Gluconate
Various strains of "medical marijuana" are found to have a significant variation in the ratios of CBD-to-THC, and are known to contain other non-psychotropic cannabinoids. Any psychoactive marijuana, regardless of its CBD content, is derived from the flower (or bud) of the genus Cannabis. Non-psychoactive hemp (also commonly-termed industrial hemp), regardless of its CBD content, is any part of the cannabis plant, whether growing or not, containing a ∆-9 tetrahydrocannabinol concentration of no more than 0.3% on a dry-weight basis. Certain standards are required for legal growing, cultivating, and producing the hemp plant. The Colorado Industrial Hemp Program registers growers of industrial hemp and samples crops to verify that the dry-weight THC concentration does not exceed 0.3%.
Hemp extract is taken from the whole plant and contains higher levels of CBD than hemp seed oil. This is where the CBD levels come from. However, we are confused by the labeling. If we expect the 500 product to have 500 mg of CBD, are we right? The label shows 500 mg of ‘phytocannabinoid hemp oil’. The solution is that about 160% of that is CBD, with the other cannabinoids as a tag along. This is effective.
Subsequent studies were carried out in different countries, which confirmed the results found in the Zammit et al. (2002) study, showing that those clinically dependent on cannabis by 18 years of age had an increased risk of later developing psychotic symptoms (Fergusson, Horwood, & Swain-Campbell, 2003). Cannabis users were also more likely to develop schizophreniform disorder (Arseneault et al., 2002), and the dose–response relationship found in the first study was confirmed (Henquet et al., 2005).
Nabiximols (brand name Sativex) is a patented medicine containing CBD and THC in equal proportions. The drug was approved by Health Canada in 2005 for prescription to treat central neuropathic pain in multiple sclerosis, and in 2007 for cancer related pain. In New Zealand Sativex® is approved for use as an add-on treatment for symptom improvement in patients with moderate to severe spasticity due to Multiple Sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
We're on the edge of a CBD explosion. The U.S. market for CBD products is estimated to be worth $2.1 billion by 2020, up 700 percent from 2016; the World Anti-Doping Agency removed CBD from its list of banned substances; the Food and Drug Administration approved an epilepsy medication containing CBD oil for the first time, causing the U.S. Drug Enforcement Administration to shift its stance — albeit very slightly — on CBD.
Consumers report using CBD for a huge variety of health and wellness reasons, but a lot more research is needed to determine which symptoms and ailments it works best for. Currently, there are more than 40 clinical trials enrolling patients to examine the effectiveness of CBD for a variety of diseases, including substance use disorder, chronic pain, post-traumatic stress disorder (PTSD), depression, schizophrenia, and many others. Most importantly, CBD is incredibly safe, and not addictive. Even young children can tolerate daily doses of up to twenty milligrams (20 mg) per kilogram (1 kg) of body weight (for a 175 pound adult, that’s more than 1,500 mg). The most common side effect of high-dose CBD is sleepiness.
Regarding health claims, the contract states: “Under no circumstances may [a distributor] prescribe any Product as suitable for a particular ailment. No claims may be made as to therapeutic or curative properties of any Product offered by the Company.” As for income claims, the contract says distributors are “prohibited from making false, misleading, or unrepresentative claims regarding earning potential.” It adds that, when an income claim reflects actual earnings, the claim must be accompanied by “the Company’s current Annual Average Income Disclosure, posted on the Company’s website.” But as of the date of publication, it was not posted there.
We went back and forth like that for several rounds, yelling at each other in 30-degree weather in front of an RV wrapped in marijuana-leaf graphics and blasting Bob Marley music. Finally, he stopped trying to enlighten me and shuffled off to let me buy my lollies in peace. As I tore into my new treats, I realized the whole thing had been a scene from the internet’s dominant cannabidiol discourse come to life: Some money had been spent and some opinions had been said, but no one had gained any information.
LEGAL NOTICES: Care By Design products have not been evaluated by the Food and Drug Administration (FDA). This information is not intended to diagnose, treat or cure any disease. This information should not be interpreted as medical advice or treatment. You should consult your physician or other health care professional before starting any medication or supplements. Further, Care By Design does not manufacture, sell or distribute any products that are in violation of California State Law.
The main difference between the two is in its chemical composition, specifically in tetrahydrocannabinol (THC). THC is the chemical responsible marijuana’s psychological effects.An average batch of marijuana contains anywhere from 5-20% THC content. Some premium marijuana can have up to 25-30% THC. Hemp, on the other hand, has a max THC level of 0.3%, essentially making it impossible to feel any psychoactive effect or get a “high”. This threshold is heavily regulated in other countries that have legalized hemp.Hemp also has high cannabidiol (CBD) content that acts as THC’s antagonist, essentially making the minimal amount of THC useless.
Hemp has been grown for millennia in Asia and the Middle East for its fibre. Commercial production of hemp in the West took off in the eighteenth century, but was grown in the sixteenth century in eastern England. Because of colonial and naval expansion of the era, economies needed large quantities of hemp for rope and oakum. In the early 1940s, world production of hemp fiber ranged from 250 000 to 350 000 metric tonnes, Russia was the biggest producer.
Systematic activities to prevent or cure health problems and promote good health in humans are undertaken by health care providers. Applications with regard to animal health are covered by the veterinary sciences. The term "healthy" is also widely used in the context of many types of non-living organizations and their impacts for the benefit of humans, such as in the sense of healthy communities, healthy cities or healthy environments. In addition to health care interventions and a person's surroundings, a number of other factors are known to influence the health status of individuals, including their background, lifestyle, and economic, social conditions and spirituality; these are referred to as "determinants of health." Studies have shown that high levels of stress can affect human health.
Hemp is not the same as marijuana. One really has nothing to do with the other. Hemp was made illegal back in the days when cotton was king in the south and southern cotton plantation owners did not want the competition. They lobbied for, and got a law against hemp being grown nationwide. It never had to do with drugs at that time, and still doesn’t. As always, money and government go hand in hand. Now, recently, South Carolina has legalized growing hemp again, which is the only state in 50 to do so. We will hope for more enlightened agri-business legislation across the nation, soon.
Fig. 11. Frequency histograms of THC concentration in germplasm collections. Left, collection of E. Small and D. Marcus; of the 167 accessions, 43% had THC levels >0.3%. Right, the collection of the Vavilov Institute, St. Petersburg; of the 278 accessions for which chemical analyses were reported in Anonymous (1975), about 55% had THC levels >0.3%.
Zammit and colleagues (2002) reported a 27-year follow-up of the Swedish cohort study. This study improved on the earlier study in the following ways: the psychiatric register provided more complete coverage of cases diagnosed with schizophrenia; and there was better statistical control of more potentially confounding variables, including other drug use, IQ, known risk factors for schizophrenia and social integration. Cannabis use at baseline predicted a dose–response relationship between the frequency of cannabis use at age 18 and the risk of schizophrenia during the follow-up. The relationship persisted after statistically controlling for the effects of other drug use and other potential confounding factors, including a history of psychiatric symptoms at baseline. They estimated that 13 percent of cases of schizophrenia could be averted if all cannabis use were prevented.